InVision Precision Cardiac Amyloid vs VX1
AI Verdict
Choose InVision Precision Cardiac Amyloid if…
Choose InVision Precision Cardiac Amyloid if your primary objective is the early and accurate detection of cardiac amyloidosis in patients presenting with heart failure symptoms, utilizing AI-powered analysis of echocardiogram studies. This tool is ideal for cardiology departments and echocardiography labs focused on improving diagnostic precision and reducing misdiagnosis of this often underdiagnosed disease.
View InVision Precision Cardiac Amyloid →Choose VX1 if…
Choose VX1 if you are a cardiac electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and require real-time AI assistance to identify dispersed electrograms. This software is best suited for EP labs aiming to enhance procedural efficiency, reduce inter-operator variability, and standardize outcomes during complex ablation interventions.
View VX1 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | InVision Precision Cardiac Amyloid | VX1 |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud or on-premise | Software integrated with existing electrophysiology (EP) lab mapping and recording systems. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
VX1Tool B (VX1) offers real-time, AI-guided assistance during complex cardiac ablation procedures, integrating with most existing EP lab mapping and recording systems. Its simple user interface provides visual and audio cues to guide the operator during a live intervention, suggesting a highly refined and interactive usability experience in a high-stakes environment.
Clinical Value
InVision Precision Cardiac AmyloidTool A (InVision Precision Cardiac Amyloid) addresses the critical need for early and accurate detection of cardiac amyloidosis, a life-threatening and often underdiagnosed disease. It boasts strong peer-reviewed evidence, including publication in JAMA Cardiology, and is uniquely FDA-cleared as a diagnostic aid even before heart failure symptoms appear, highlighting a profound and validated clinical impact.
Pricing & Value
InVision Precision Cardiac AmyloidTool A (InVision Precision Cardiac Amyloid) provides transparent pricing, starting at $49/month for a subscription, with options for enterprise and volume discounts. This clear pricing structure allows potential users to easily assess the initial cost and value proposition. Tool B (VX1), in contrast, only states 'contact for pricing,' which lacks transparency.
Enterprise Readiness
InVision Precision Cardiac AmyloidTool A (InVision Precision Cardiac Amyloid) demonstrates strong enterprise readiness with explicit HIPAA compliance, FDA clearance, and the establishment of a CPT Category III code (0932T) for reimbursement, effective January 1, 2025. This comprehensive regulatory and reimbursement framework significantly streamlines its adoption within healthcare systems.
Innovation
VX1Tool B (VX1) stands out for its pioneering achievement as the first FDA-cleared AI tool in interventional cardiac electrophysiology, providing real-time, AI-guided decision support during complex ablation procedures. Its ability to analyze 3D anatomical and electrical maps of the human atria in real-time represents a highly innovative application of AI in a live interventional setting.
Support & Docs
VX1Tool B (VX1) explicitly mentions and provides access to a 'User Manual' and 'Technical Documentation' for its product, indicating readily available and structured support resources. For Tool A, while contact information is available, specific documentation or a dedicated support portal for 'InVision Precision Cardiac Amyloid' was not clearly found in the search results.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | InVision Precision Cardiac Amyloid | VX1 |
|---|---|---|
| Product Name | InVision Precision Cardiac Amyloid | VX1 |
| Company | InVision Medical Technology Corporation | Volta Medical |
| Primary Application | AI-powered software for echocardiography to detect cardiac amyloidosis. | AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during ablation procedures. |
| Target Condition(s) | Cardiac amyloidosis (AL and ATTR types) | Atrial fibrillation (AFib) and atrial tachycardia |
| Key AI Functionality | AI-powered detection of cardiac amyloidosis; Evaluation of transthoracic echocardiogram studies; Precise assessment of wall thickness. | AI-guided real-time identification of dispersed electrograms (EGMs); Analyzes 3D anatomical and electrical maps; Provides cycle length estimation. |
| Target Specialty | Cardiology, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and VX1.